Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Intravesical Gemcitabine for Low Risk Superficial Bladder Cancer
NCT00191711Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine in non-muscle-invasive bladder cancer (NMIBC), sponsored by Eli Lilly and Company. Primary endpoint: Pathological Complete Response Rate. Started Feb 2004; status: completed.
02
Drugs
gemcitabine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT00191711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191711.